Monitor the November 2 earnings call for Q1 FY2027 results and any strategic commentary from outgoing CEO Rendle and CFO Bellet. Garcia's appointment removes leadership uncertainty but the company still faces declining revenue and earnings per the prior proxy statement.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 29 $88.67entry
- T+1 · 6d ago −0.76%α +1.02% · $88.00
- T+4 · todayOpen
- T+5 · in 11h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Clorox filed a DEFA14A supplement to its proxy statement disclosing the appointment of Fabian Garcia as CEO effective January 5, 2027, succeeding Linda Rendle who is stepping down for health reasons. The filing also details Garcia's compensation package and Rendle's advisory transition, but does not change the matters to be voted on at the November 18, 2026 annual meeting.
Key Financial Metrics
Key Facts
- Fabian Garcia appointed CEO effective January 5, 2027, succeeding Linda Rendle who steps down for health reasons
- Garcia to receive $100,000 annual base salary, $2,000,000 target short-term incentive, $4,550,000 pro-rated long-term incentive, and $11,000,000 sign-on RSU award
- Matthew Shattock to become independent chair upon Garcia's appointment
- Rendle to serve as senior advisor through April 2, 2027 with $1,350,000 salary
- Annual meeting remains scheduled for November 18, 2026 with no changes to proposals
Financial Impact
CEO compensation package with total target annual value of approximately $11.2M ($100K salary + $2M bonus + $9.1M LTI) plus $11M one-time sign-on award; no material impact on company financials
Risk Factors
- CEO transition period runs through January 5, 2027 with potential execution risk
- Garcia has no prior experience at Clorox and is joining from a competitor (Unilever)
- Company reported 5% net sales decline and 28% earnings decline in prior filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001206774-26-000587 |
| Document: 0001206774-26-000587-index-headers.html | 0001206774-26-000587 |
| Document: 0001206774-26-000587-index.html | 0001206774-26-000587 |
| Document: 0001206774-26-000587.txt | 0001206774-26-000587 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 2, 2026 2d ago | 8-K | No price | awaiting T+5 | awaiting T+5 | No price |
Nov 2, 2026 2d ago | Press Release | $93.80 | awaiting T+5 | awaiting T+5 | $93.80 (+0.00%) |
Oct 29, 2026 6d ago | DEFA14A | $88.67 | awaiting T+5 | awaiting T+5 | $93.80 (+5.79%) |
Oct 29, 2026 6d ago | 8-K | $88.67 | awaiting T+5 | awaiting T+5 | $93.80 (+5.79%) |
Oct 27, 2026 8d ago | SC 13G/A | $86.84 $99.16 | ▲ +14.19% | ▲ +14.90% | $93.80 (+8.01%) |
Oct 16, 2026 19d ago | Institutional Cluster | $85.56 $86.35 | ▲ +0.92% | ▲ +1.06% | $93.80 (+9.63%) |
Oct 7, 2026 28d ago | DEFA14A | $83.44 $86.20 | ▲ +3.31% | ▲ +3.58% | $93.80 (+12.42%) |
Oct 7, 2026 28d ago | DEF 14A | $83.44 $86.20 | ▼ −3.31% | ▼ −3.58% | $93.80 (−12.42%) |
Sep 23, 2026 6w ago | Press Release | $81.80 $80.65 | ▼ −1.41% | ▼ −0.99% | $93.80 (+14.67%) |
Aug 26, 2026 10w ago | Institutional Cluster | $104.23 $94.27 | ▼ −9.56% | ▼ −9.44% | $93.80 (−10.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers